Targeting CLEC9A, a CLR with advantageously restricted expression on cDC1 DCs, also elicited anti-tumor responses in multiple studies, coherent with the potent (cross-)presenting function of these DCs (112, 113). The gene discussed is CLEC9A; the disease is neoplasm.